Abstracts tagged "Economics"

Abstract Number: 2497 • 2017 ACR/ARHP Annual Meeting
The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study
Santiago Rodrigues Manica^1,2, Alexandre Sepriano^3,4, Sofia Ramiro^5,6, Fernando Pimentel-Santos^1,2, Polina Putrik⁷, Elena Nikiphorou^8,9, Anna Moltó^10,11, Maxime Dougados^11,12, Désirée van der Heijde¹³, Robert B.M. Landewé¹⁴, Filip van Den Bosch¹⁵ and Annelies Boonen⁷, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, ³CEDOC, NOVA Medical School, Lisboa, Portugal, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶R. Câmara Pestana 6, CEDOC, NOVA Medical School, Lisbon, Portugal, ⁷MUMC+, Maastricht, Maastricht, Netherlands, ⁸Whittington Hospital, London, United Kingdom, ⁹Academic Rheumatology Department, King's College London, London, United Kingdom, ¹⁰Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP,Paris, Paris, France, ¹¹7 INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France, ¹²Paris, Paris, France, ¹³Leiden University Medical Center, Leiden, Netherlands, ¹⁴Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ¹⁵Rheumatology, Ghent University Hospital, Gent, Belgium
Background/Purpose: Spondyloarthritis (SpA) carries substantial financial costs, including direct costs (use of medical services and treatments) and indirect costs (loss of work productivity). While disease…
Abstract Number: 1237 • 2016 ACR/ARHP Annual Meeting
The Economic Burden of Dermatomyositis and Polymyositis in the US
J. Bradford Rice¹, Alan White¹, Philip Galebach¹, Andrea Lopez¹, Patricia Schepman², Breanna Popelar³, Michael Philbin⁴ and Elaine Boing², ¹Analysis Group, Inc., Boston, MA, ²Affiliated with Mallinckrodt Pharmaceuticals at the time this study was conducted, Hazelwood, MO, ³Xcenda, L.L.C., Palm Harbor, FL, ⁴Mallinckrodt Pharmaceuticals, Hazelwood, MO
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies that can lead to persistent muscle weakness and disability. Although significant healthcare resource utilization (HCRU) and work…
Abstract Number: 1243 • 2016 ACR/ARHP Annual Meeting
Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis
Cécile Gaujoux-Viala¹, Laure Gossec², Christel Castelli³, Cédric Lukas⁴, Françoise Barchechath-Flaisler⁵, Jean-Pierre Daures⁶ and Maxime Dougados⁷, ¹Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³BESPIM, Nîmes University Hospital and EA2415, Nîmes, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Nîmes University Hospital, Rheumatology Department, Nimes, France, ⁶EA2415, Nîmes, France, ⁷Paris Descartes University, Paris, France
Background/Purpose: The quantification of health improvements is essential, notably in the current context of increasingly expensive therapies and more and more limited resources. Preference-based measures…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 2252 • 2016 ACR/ARHP Annual Meeting
Estimated Cost of SLE Hospitalizations
Kayla Neville¹, James Miceli¹, Jianhua Li², Samantha Nguyen³, Teja Kapoor³ and Anca Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, ³Medicine, Division of Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) treatment comes at a high price, with both direct costs related to healthcare resource utilization and indirect ones related to…
Abstract Number: 113 • 2016 ACR/ARHP Annual Meeting
Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Fei Xiao¹, Xiangyuan Liu², Zhijun Li³, Tong Xie⁴, Xinwang Duan⁵, Huiqiong Zhou⁶, Yanhong Huang⁷, Yi Zheng⁸, Hua Wei⁹, Hongzhi Wang¹⁰, Rong Mu¹¹, Hui Xiao¹, Yuhua Jia¹, Yonggang Zhao¹, Yuan Liu¹ and Fengchun Zhang¹², ¹Gothic Internet Technology Corporation, Shanghai, China, ²Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ³The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁴Affiliated hospital of Guangdong medical University, Zhanjiang, China, ⁵Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁶The First Affiliated Hospital of PLA General Hospital, Beijing, China, ⁷Beijing Jishuitan Hospital, Beijing, China, ⁸8 Gongren Tiyuchang Nanlu, Cha, Beijing Chao-Yang Hospital, Beijing, China, ⁹No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ¹⁰The First Hospital of Jiaxing, Jiaxing, China, ¹¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ¹²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: China does not have primary medical care and referral system. Patients can choose any hospital or any doctor they like to seek medical care.…
Abstract Number: 228 • 2016 ACR/ARHP Annual Meeting
Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Valgerdur R Sigurdardottir¹, Lennart TH Jacobsson², Panagiota Drivelegka², Anna Svärd^1,3 and Mats Dehlin², ¹Rheumatology Clinic, Falun Hospital, SE-791 82 Falun, Sweden, Falun, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Clinical Research Dalarna, Falun, Sweden
Background/Purpose: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50-59 years. Gout…
Abstract Number: 123 • 2015 ACR/ARHP Annual Meeting
An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US
Lindsay Claxton¹, Matthew Taylor¹, Michelle Jenks¹, Gene Wallenstein², Alan Mendelsohn³, Jeffrey Bourret³, Amitabh Singh³ and Robert Gerber², ¹York Health Economics Consortium, University of York, York, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). An economic model was developed to evaluate the treatment…
Abstract Number: 144 • 2015 ACR/ARHP Annual Meeting
One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Tao Gu¹, Derek Tang², Gaurav Deshpande¹, Debra F Eisenberg¹ and David J. Harrison³, ¹HealthCore, Wilmington, DE, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate…
Abstract Number: 145 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis
Zheng-Yi Zhou¹, Jenny Griffith², Arijit Ganguli², Ella Xiaoyan Du¹ and Keith Betts¹, ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Real world studies comparing the healthcare utilization of anti-TNFs vs. non-TNFs as the next alternative after the failure of the first anti-TNF are scarce.…
Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Douglas C. Wolf¹, Martha Skup², Hongbo Yang³, Elizabeth Faust³, Jenny Griffith², Jingdong Chao² and Mark Lebwohl⁴, ¹Atlanta Gastroenterology Associates, Atlanta, GA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Mount Sinai Medical Center, New York, NY
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre¹, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Xabier Barber³, Ana Pons⁴, Catalina Cano⁴, Marisa Lorente⁵ and Juan Molina⁶, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ³Centro de Investigación Operativa, Miguel Hernández University, Elche, Spain, ⁴Hospital Marina Baixa, Nursing, Villajoyosa, Spain, ⁵Marina Baixa Hospital, Nursing, Villajoyosa, Spain, ⁶Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…
Abstract Number: 989 • 2015 ACR/ARHP Annual Meeting
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis
Megan Barber¹, John G. Hanly², Aidan O'Keeffe³, Li Su⁴, Murray Urowitz^5,6, Yvan St. Pierre⁷, Juanita Romero-Diaz⁸, C. Gordon⁹, Sang-Cheol Bae¹⁰, Sasha Bernatsky¹¹, Daniel J Wallace¹², Joan T. Merrill¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Ellen M. Ginzler¹⁶, Paul R. Fortin¹⁷, Dafna D. Gladman¹⁸, Jorge Sanchez-Guerrero¹⁹, Michelle Petri²⁰, Ian N. Bruce²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Cynthia Aranow²⁴, Graciela S. Alarcon²⁵, W. Winn Chatham²⁶, Kristján Steinsson²⁷, Ola Nived²⁸, Gunnar K. Sturfelt²⁹, Susan Manzi³⁰, Munther Khamashta³¹, Ronald F. van Vollenhoven³², Asad Zoma³³, Manel Ramos-Casals³⁴, Guillermo Ruiz-Irastorza³⁵, S. Sam Lim³⁶, Thomas Stoll³⁷, Murat Inanc³⁸, Kenneth C. Kalunian³⁹, Diane L. Kamen⁴⁰, Peter Maddison⁴¹, Christine A. Peschken⁴², Søren Jacobsen⁴³, Anca Askanase⁴⁴, Jill P. Buyon⁴⁵, Chris Theriault⁴⁶, Kara Thompson⁴⁶, Vernon Farewell⁴⁷ and Ann E. Clarke⁴⁸, ¹Division of Rheumatology, University of Calgary, Caglary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Statistical Science, University College London, London, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico, ⁹School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ¹²Cedars-Sinai Medical Center, West Hollywood, CA, ¹³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁶Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁷Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁸Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²⁰Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²²UNC Kidney Centre, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Feinstein Institute for Medical Research, Mahasset, NY, ²⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁶Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁷Centre for Rheumatology Research, Landspital University Hospital, Reykjavik, Iceland, ²⁸Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁰Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³¹Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³³Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Autoimmune Disease Research Unit, Service of Internal Medicine, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, ³⁶Emory University School of Medicine, Atlanta, GA, ³⁷Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³⁸Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ⁴⁰Medicine, Medical University of South Carolina, Charleston, SC, ⁴¹Musculoskeletal Medicine, Bangor University, Bangor, United Kingdom, ⁴²Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴³Department of Rheumatology,, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴⁴Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴⁶Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term healthcare costs were compared between SLE patients with and…
Abstract Number: 1001 • 2015 ACR/ARHP Annual Meeting
What Is the Most Cost-Effective Physical Therapy Strategy to Treat Knee Osteoarthritis?
Allyn Bove¹, Ken Smith², Christopher Bise¹, Julie Fritz³, John Childs⁴, Gerard P. Brennan⁵, J. Haxby Abbott⁶ and G. Kelley Fitzgerald¹, ¹Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Division of Internal Medicine; Institute for Clinical Research Education, University of Pittsburgh, Pittsburgh, PA, ³Department of Physical Therapy, University of Utah, Salt Lake City, UT, ⁴US Army-Baylor University, Schertz, TX, ⁵Rehabilitation Services, Intermountain Healthcare, Murray, UT, ⁶Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand
Background/Purpose: The American College of Rheumatology (ACR) strongly recommends exercise therapy as a first-line conservative treatment for individuals with knee osteoarthritis (OA).1 Evidence supporting manual…
Abstract Number: 1270 • 2015 ACR/ARHP Annual Meeting
Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Estimates of the healthcare costs of Granulomatosus with polyangiitis (GPA) and predictors of costs are scarce. In particular, while socioeconomic status (SES) is associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].